Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Logistic regression analyses using signature scores to predict CDAI nonremission at 6 months of biologic therapy

From: Identification of baseline gene expression signatures predicting therapeutic responses to three biologic agents in rheumatoid arthritis: a retrospective observational study

Drug Gene set Univariate analysis Multivariate analysisa
OR 95 % CI p Value OR 95 % CI p Value
IFX        
  Inflammasomes 1.81 (1.23–2.78) 0.00382 1.72 (1.14–2.71) 0.00873
TCZ        
  Specific CD19 (Watkins et al., 2009 [15]) 0.24 (0.05–0.72) 0.02677 0.16 (0.02–0.71) 0.01327
ABT        
  Elongation arrest and recovery 5.73 (1.47–49.11) 0.04488 6.85 (1.09–4426.71) 0.03309
  Specific CD56 (Watkins et al., 2009 [15]) 3.25 (1.18–12.43) 0.04179 6.46 (1.60–88.39) 0.00388
  1. Abbreviations: CDAI clinical disease activity index, IFX infliximab, TCZ tocilizumab, ABT abatacept, OR odds ratio, CI confidence interval, csDMARD conventional synthetic disease-modifying antirheumatic drug, MTX methotrexate, ESR erythrocyte sedimentation rate
  2. aMultivariate analysis adjusted for significant (p < 0.1) variables as in Additional file 4 (IFX: female, concomitant csDMARD use [except MTX], ESR, CDAI; TCZ: disease duration, CDAI; ABT: disease duration, concomitant steroid use)